Publication

EHA •
14 June, 2024 •
•

A European retrospective study to describe real-world outcomes, treatment patterns and resource use in primary idiopathic thrombocytopenic purpura patients treated with avatrombopag: Interim results

Francesco Zaja, Quentin Hill, Fiona Glen, Fatemeh Saberi Hosnijeh, Luca Le Treust, Lara Groves, Milica Putnik, Carly Rich

Publication

EHA •
14 June, 2024 •
•

Impact of thrombopoietin receptor agonists and adherence to instructions for treatment of chronic primary immune thrombocytopenia: interim results of a real-world cross-sectional international survey

Srikanth Nagalla, Cecilie Yssing, Donatella Decise, Milica Putnik, Carly Rich

Publication

EHA •
14 June, 2024 •
•

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Interim Analysis Results

Srikanth Nagalla, My Levy, Shruti Chaturvedi, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Kirthana Sarathy, Loren Ormenaj, Michael Vredenburg , Scott Kolodny

Symposium

EHA •
13 June, 2026 •
•

From Labs to Lives: Redefining Success in Rare Diseases Paroxysmal Nocturnal Haemoglobinuria (PNH) and Chronic Immune Thrombocytopenia (ITP)

Danny Hsu, Ana Boban, María L Lozano

Available materials

Video

Publication

A Phase 3, Randomised, Double-Blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Paediatric Subjects with Immune Thrombocytopenia (AVA-PED-301)

A European retrospective study to describe real-world outcomes, treatment patterns and resource use in primary idiopathic thrombocytopenic purpura patients treated with avatrombopag: Interim results

Impact of thrombopoietin receptor agonists and adherence to instructions for treatment of chronic primary immune thrombocytopenia: interim results of a real-world cross-sectional international survey

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Interim Analysis Results

From Labs to Lives: Redefining Success in Rare Diseases Paroxysmal Nocturnal Haemoglobinuria (PNH) and Chronic Immune Thrombocytopenia (ITP)

Avatrombopag in TPO RA–naive adults in acute, persistent, and chronic phases of ITP: results from the REAL AVA 3.0 retrospective study

Impact of protocol mandated dose holds on platelet response durability in pediatric ITP treated with avatrombopag: AVA 301 post hoc analysis

Patient-reported outcomes of avatrombopag for chronic immune thrombocytopenia: Interim analysis of the Phase 4 adopt study